Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIL 284 (Amelubant) in Healthy Male Volunteers
NCT02265302Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 1998
- Primary completion
- Dec 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amelubant in rheumatoid arthritis (RA), cystic fibrosis (CF), asthma and 1 more (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with clinically relevant changes in vital signs up to 8 days, Number of subjects with clinically relevant changes in electrocardiogram up to 8 days and 3 more. Started Jun 1998; status: completed.
02
Drugs
amelubant
03
Conditions
rheumatoid arthritis (RA)cystic fibrosis (CF)asthmapsoriasis
Beyond the preview
Go deeper on NCT02265302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265302.